OraSure Technologies Inc
NASDAQ:OSUR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.75
8.35
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
OraSure Technologies Inc
OraSure Technologies Inc
Cash & Cash Equivalents
OraSure Technologies Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
OraSure Technologies Inc
NASDAQ:OSUR
|
Cash & Cash Equivalents
$278.6m
|
CAGR 3-Years
27%
|
CAGR 5-Years
27%
|
CAGR 10-Years
11%
|
|
|
Haemonetics Corp
NYSE:HAE
|
Cash & Cash Equivalents
$299.3m
|
CAGR 3-Years
16%
|
CAGR 5-Years
22%
|
CAGR 10-Years
9%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Cash & Cash Equivalents
$312.5m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Cash & Cash Equivalents
$1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
16%
|
CAGR 10-Years
19%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Cash & Cash Equivalents
$866.4m
|
CAGR 3-Years
112%
|
CAGR 5-Years
62%
|
CAGR 10-Years
41%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Cash & Cash Equivalents
$523.1m
|
CAGR 3-Years
97%
|
CAGR 5-Years
70%
|
CAGR 10-Years
55%
|
|
OraSure Technologies Inc
Glance View
OraSure Technologies, Inc. engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. The company is headquartered in Bethlehem, Pennsylvania and currently employs 785 full-time employees. The firm's products include molecular sampling kits for the genome and microbiome services and analytics, rapid diagnostics for infectious disease, and tests for substance abuse. OraSure’s segments include Diagnostics segment and Molecular Collection Systems segment. The Diagnostics business primarily consists of the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices. The Molecular Solutions business consists of the manufacture and sale of kits that are used to collect, stabilize, transport and store biological samples of genetic material for molecular testing in the consumer genetic, clinical genetic, academic research, infectious disease diagnostics, pharmacogenomics, personalized medicine, microbiome and animal genetics markets.
See Also
What is OraSure Technologies Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
278.6m
USD
Based on the financial report for Sep 30, 2024, OraSure Technologies Inc's Cash & Cash Equivalents amounts to 278.6m USD.
What is OraSure Technologies Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
11%
Over the last year, the Cash & Cash Equivalents growth was 28%. The average annual Cash & Cash Equivalents growth rates for OraSure Technologies Inc have been 27% over the past three years , 27% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
